

July 18, 2018

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai-400051

Re.: Press Release.

Dear Sir / Madam,

We enclose herewith a copy of press release dated July 18, 2018 titled "Zydus receives four consecutive ANDA approvals from the USFDA."

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives four consecutive ANDA approvals from the USFDA

Ahmedabad, 18 July, 2018

Zydus Cadila announced that it has received four consecutive final approvals from the USFDA to market Olanzapine Tablets USP, Glipizide Extended-Release Tablets, Voriconazole for Injection and Fluocinonide Topical Solution USP.

Olanzapine Tablets USP (US RLD – Zyprexa Tablets) approved in strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg, are used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder). It may also be used in combination with other medications to treat depression. Glipizide Extended-Release Tablets (US RLD - Glucotrol XL), 2.5 mg, 5 mg, and 10 mg, are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Voriconazole for Injection (US RLD –Vfend for Injection), 200 mg single-dose vial is indicated for use in patients, 12 years of age and older in the treatment of invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis and serious fungal infections. These three products will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.

Fluocinonide Topical Solution USP, 0.05% (US RLD - Lidex Topical Solution) is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies and rash) and reduces the swelling, itching, and redness that can occur in these types of conditions. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

In line with this, the group now has 208 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 22,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
